PUBLISHER: Global Insight Services | PRODUCT CODE: 2171091
PUBLISHER: Global Insight Services | PRODUCT CODE: 2171091
The global Exocrine Pancreatic Insufficiency Treatment Market is projected to grow from $4.2 billion in 2025 to $6.8 billion by 2035, at a compound annual growth rate (CAGR) of 4.9%. A single authoritative global market-size or CAGR series for EPI treatments is not published by major government statistical agencies; therefore, disease-burden and commercial indicators provide a more transparent market proxy. NIDDK reports that pancreatic enzyme dysfunction occurs in up to 90% of people with chronic pancreatitis and 80%90% of people with cystic fibrosis. Global pancreatic cancer incidence reached 531,318 cases in 2024, according to IARC, expanding the population requiring assessment for pancreatic functional impairment. Commercial demand is also reflected by AbbVies Creon revenue of $1.512 billion in 2025, up 9.3% from 2024.
Pancreatic enzyme replacement therapy (PERT) represents the core treatment approach, supplying lipase, protease, and amylase to compensate for deficient endogenous enzymes and improve digestion. FDA-approved pancrelipase products are indicated for EPI associated with conditions including cystic fibrosis, chronic pancreatitis, and pancreatic surgery. Nutritional supplements, including fat-soluble vitamins and minerals, address deficiencies resulting from impaired nutrient absorption. Lifestyle modifications, including dietary adjustment, adequate caloric intake, and avoidance of aggravating factors, complement pharmacological management. PERT demand is supported by its established clinical role, while nutritional management and integrated care are gaining importance as diagnosis and long-term disease management improve.
| Market Segmentation | |
|---|---|
| Type | Prescription Drugs, Over-the-Counter Drugs, Others |
| Product | Pancreatic Enzyme Replacement Therapy (PERT), Others |
| Technology | Enzyme Formulation Technology, Others |
| Component | Lipase, Protease, Amylase, Others |
| Application | Chronic Pancreatitis, Cystic Fibrosis, Pancreatic Cancer, Post-Surgical Conditions, Others |
| Form | Tablets, Capsules, Powders, Others |
| Process | Manufacturing, Distribution, Others |
| End User | Hospitals, Clinics, Homecare Settings, Others |
| Mode | Oral Administration, Others |
| Stage | Clinical Trials, Commercialization, Others |
Chronic pancreatitis constitutes a major application because progressive pancreatic damage can substantially reduce digestive enzyme secretion; NIDDK estimates pancreatic enzyme problems may occur in 30%90% of people with chronic pancreatitis. Cystic fibrosis represents another established indication, with enzyme-related pancreatic dysfunction affecting approximately 80%90% of patients. Pancreatic cancer and post-surgical conditions create additional treatment demand through pancreatic tissue loss or impaired secretion. PERT improves nutrient digestion and helps manage malabsorption, while nutritional interventions support weight maintenance and micronutrient status. Expansion of specialized pancreatic care, increasing disease recognition, and longer-term management requirements support continued demand across these applications.
North America maintains a substantial position in the EPI treatment market through established gastroenterology infrastructure, specialist pancreatic centers, advanced diagnostic capabilities, and comparatively high access to prescription therapies. The United States provides a large addressable patient base across chronic pancreatitis, cystic fibrosis, pancreatic cancer, and surgical populations. Regulatory pathways have supported commercialization of pancrelipase products, while FDA documentation recognizes EPI associated with cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions. The region also benefits from established reimbursement systems, patient-support programs, clinical research, and pharmaceutical manufacturing capabilities. Continued investment in digestive-disease care and precision nutritional management is supporting sustained treatment adoption.
Asia-Pacific presents substantial expansion opportunities as healthcare infrastructure, specialist diagnosis, and access to pancreatic therapies improve across major economies. Japan, China, India, South Korea, and Australia represent important healthcare markets with growing capabilities for gastrointestinal disease management and oncology care. IARC recorded 243,861 pancreatic cancer cases in Asia in 2024, representing a significant underlying population requiring pancreatic-function assessment. Increasing healthcare expenditure, expansion of specialist hospitals, wider availability of diagnostic services, and pharmaceutical-market development are improving treatment accessibility. Greater awareness of malabsorption and nutritional complications, alongside broader adoption of enzyme replacement therapy, can support long-term market development across the region.
Personalized Enzyme Therapy Reshapes EPI Treatment Strategies
The market is shifting toward integrated EPI management that combines enzyme replacement with nutritional monitoring and individualized dietary intervention. PERT formulations increasingly emphasize controlled enzyme release and dosing according to meal composition, body weight, symptoms, and treatment response. FDA prescribing information for pancrelipase products specifies individualized dosing and monitoring based on clinical factors, reinforcing the move toward personalized treatment management. At the care-delivery level, greater attention to fat-soluble vitamin deficiencies, weight maintenance, bone health, and long-term nutritional outcomes is encouraging multidisciplinary approaches involving gastroenterologists, dietitians, and specialist care teams.
Rising Pancreatic Disease Burden Expands Treatment Demand
The expanding clinical burden of diseases associated with pancreatic enzyme dysfunction is strengthening demand for EPI treatment. Chronic pancreatitis can progressively damage pancreatic tissue, while cystic fibrosis is strongly associated with pancreatic insufficiency; NIDDK estimates pancreatic enzyme problems in 30%90% of chronic-pancreatitis patients and 80%90% of people with cystic fibrosis. Pancreatic cancer and pancreatic surgery further expand the treatment population. Rising recognition of malabsorption, improved diagnostic evaluation, and greater emphasis on maintaining nutritional status encourage physicians to initiate and optimize enzyme replacement therapy, supporting recurring demand for pancrelipase-based treatments.
Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.